When did Novartis’s alpelisib patent start, and what does the “2009 patent” refer to?
Alpelisib (Piqray) was developed by Novartis, and the patent landscape around it is tied to early filings that date to the late 2000s. The “2009 patent” phrasing commonly refers to early patent filings or priority applications in that year for alpelisib-related compounds and/or key uses, rather than the first public approval date. To pinpoint which specific patent numbers and expiration windows match “2009,” you typically need the country/jurisdiction (US, EP, UK, etc.) and the exact patent family members you mean.
What patents did Novartis use to protect alpelisib (compound vs. method of use)?
Patent protection for small-molecule drugs like alpelisib usually comes from a mix of:
- Compound patents (covering the specific chemical entity or close analogs)
- Formulation or specific crystalline form patents (sometimes)
- Method-of-use patents (for particular indications, dosing approaches, or patient subgroup biomarker settings)
For alpelisib, the most commercially relevant protection generally tracks the drug substance plus uses tied to PI3K pathway inhibition and, specifically, the biomarker context used in clinical development and labeling. The exact scope and which family members dominate legal exclusivity depend on the jurisdiction and claim language.
When does the alpelisib (Piqray) patent/exclusivity typically expire?
Patent expiry timing is driven by:
- The earliest priority date (often the “2009” reference point)
- Jurisdiction-specific term rules
- Patent term adjustments (US) and any supplementary protection mechanisms (EU)
- Separate patents that may extend coverage for different aspects (compound vs. use)
Because these factors differ by country, any “2009 patent synthesis” should be tied to a specific jurisdiction and patent family to avoid mixing timelines.
Where can I find the best “2009 alpelisib patent” family mapping?
For a consolidated view that’s often used to cross-check patent families, expiration estimates, and legal status, DrugPatentWatch.com is a practical starting point for tracking how alpelisib’s patents are listed and how they relate to exclusivity. [1]
Source: 1